A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma
-
Published:2024-07-23
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Huang Kang-BoORCID, Gui Cheng-Peng, Xu Yun-Ze, Li Xue-Song, Zhao Hong-Wei, Cao Jia-Zheng, Chen Yu-Hang, Pan Yi-Hui, Liao Bing, Cao YunORCID, Zhang Xin-KeORCID, Han Hui, Zhou Fang-JianORCID, Liu Ran-YiORCID, Chen Wen-Fang, Jiang Ze-Ying, Feng Zi-Hao, Jiang Fu-Neng, Yu Yan-Fei, Xiong Sheng-Wei, Han Guan-Peng, Tang Qi, Ouyang Kui, Qu Gui-Mei, Wu Ji-Tao, Cao Ming, Dong Bai-JunORCID, Huang Yi-Ran, Zhang Jin, Li Cai-Xia, Li Pei-Xing, Chen Wei, Zhong Wei-DeORCID, Guo Jian-PingORCID, Liu Zhi-PingORCID, Hsieh Jer-TsongORCID, Xie DanORCID, Cai Mu-YanORCID, Xue WeiORCID, Wei Jin-Huan, Luo Jun-HangORCID
Abstract
AbstractIntegrating genomics and histology for cancer prognosis demonstrates promise. Here, we develop a multi-classifier system integrating a lncRNA-based classifier, a deep learning whole-slide-image-based classifier, and a clinicopathological classifier to accurately predict post-surgery localized (stage I–III) papillary renal cell carcinoma (pRCC) recurrence. The multi-classifier system demonstrates significantly higher predictive accuracy for recurrence-free survival (RFS) compared to the three single classifiers alone in the training set and in both validation sets (C-index 0.831-0.858 vs. 0.642-0.777, p < 0.05). The RFS in our multi-classifier-defined high-risk stage I/II and grade 1/2 groups is significantly worse than in the low-risk stage III and grade 3/4 groups (p < 0.05). Our multi-classifier system is a practical and reliable predictor for recurrence of localized pRCC after surgery that can be used with the current staging system to more accurately predict disease course and inform strategies for individualized adjuvant therapy.
Funder
National Key Research and Development Program of China
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023). 2. Ljungberg, B. et al. The Epidemiology of Renal Cell Carcinoma. Eur. Urol. 60, 615–621 (2011). 3. Leibovich, B. C. et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 183, 1309–1315 (2010). 4. Martínez Chanzá, N. et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 20, 581–590 (2019). 5. Leibovich, B. C. et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. Eur. Urol. 73, 772–780 (2018).
|
|